Reminyl is one of the most common drugs presently used for treatment of mild to moderate Alzheimer. The present study is an attempt to investigate the influence of presenting two innovative nano-engineered drug carriers (Ce/Ca-HAp& CMCS/Ce/Ca-HAp) as carriers for Rem in Alz therapy. A total of 86 adult female albino Wistar rats were randomly assigned to the following groups: Control group (C) of 8 rats given saline; Reminyl group (Rem) of 8 rats treated with Rem; Alzheimer's group (Alz) of 16 ovariectomized animals inoculated orally with AlCl₃ (17mg/Kg b.wt/day) for 2 months after 6 weeks of surgical operation; Alzheimer's disease-induced rats treated (i.p) with Rem (2.5mg/Kg b.wt/day); Alzheimer's disease-induced rats treated (i.p) with Rem coated by Ce/Ca-HAp (2.5mg/Kg b.wt/day) and Alzheimer's disease-induced rats treated (i.p) with Rem coated by CMCS/Ce/Ca-HAp (2.5mg/Kg b.wt/day). After 2 and 4 weeks animals were sacrificed by ether inhalation anesthesia where brains were removed and processed for histological analysis by Hx&E and biochemical analysis for measuring GSH, SOD, CAT and CytoP450reductase levels. Histological and biochemical alterations designated in Rem treated rat brains were ameliorated following the use of Rem coated by Ce/Ca-HAp and not with Rem coated by CMCS/Ce/Ca-HAp. Initiation of new nano drug delivery systems may attribute in delivery of therapeutic drug to the site of action and overcome drawbacks of the drug alone.